Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10

作者：Lothar Steidler, Wolfgang Hans, L. Schotte, Sabine Neirynck, Florian Obermeier, Werner Falk, Walter Fiers, Erik Remaut · 发表于：Science · 年份：2000 · DOI：10.1126/science.289.5483.1352 · 被引用次数：1480 · 研究领域：Immune Response and Inflammation、Probiotics and Fermented Foods、Infant Nutrition and Health

The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10(-/-) mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans.